Effects of short-course buserelin therapy on adenomyosis. A report of two cases.

The Journal of reproductive medicine · 1999 · vol. 44(8) , pp. 741–4 · PMID:10483548 · W97648749
article OA: closed CC0 ⤵ 50 in-corpus citations
View on OpenAlex View on PubMed
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-13 ⓘ

Two adenomyosis patients treated with a three-month GnRH-a nasal spray experienced symptom relief and conceived within six months of stopping treatment.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

BACKGROUND: Hysterectomy and hysteroscopic endometrial ablation remain common treatment of symptomatic adenomyosis for women who have completed childbearing. However, for patients who wish to avoid surgery and in whom adenomyosis is suspected of causing infertility, repeated abortion or physical symptoms, medical treatment with gonadotropin-releasing hormone analogue (GnRH-a) should be considered. CASES: Two cases of documented adenomyosis were suspected of causing infertility; both were treated with a three-month course of GnRH-a via a nasal spray. Both patients experienced relief of symptoms and conceived within six months of the cessation of treatment. CONCLUSION: The efficacy and safety of a short course of GnRH-a treatment of adenomyosis may be considered in patients who take less time than others to achieve a significant reduction of uterine size and relief of symptoms and in those who develop side effects.

My notes (saved in your browser only)

Condition tags

endometriosisadenomyosisinfertility

MeSH descriptors

Antineoplastic Agents, Hormonal Buserelin Endometriosis Administration, Intranasal Adult Antineoplastic Agents, Hormonal Antineoplastic Agents, Hormonal Buserelin Buserelin Drug Administration Schedule Endometriosis Endometriosis Female Humans Pregnancy Treatment Outcome

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

Cited by (50)

Source provenance

europepmc
last seen: 2026-09-27T09:11:36.575535+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:10:24.024533+00:00
License: CC0 · commercial use OK